Abstract
Antibody drug conjugates are emerging as a powerful class of anti-tumor agents with efficacy across a range of cancers; therefore, understanding the disposition of this class of therapeutic is crucial. Reported here, is a method to enrich a specific organelle (lysosome) to understand the catabolism of an anti-CD70 Ab-MCC-DM1, an antibody drug conjugate with a non-cleavable linker. With such techniques a higher degree of concentration-activity relationship can be established, aiding in dose selection of the antibody drug conjugate.
- biologics/therapeutic proteins
- cellular trafficking/localization
- drug development/discovery
- mass spectrometry/MS
- metabolite disposition
- The American Society for Pharmacology and Experimental Therapeutics